BeiGene, Ltd., a global oncology company that will change its name to BeOne Medicines Ltd., announced it will share 23 abstracts featuring new data across its hematology and solid… read more.
Jazz Pharmaceuticals plc announced that the Committee for Medicinal Products for Human Use (CHMP) of the EMA has adopted a positive opinion recommending the conditional marketing authorization of… read more.
Presented at ESTRO 2025, which gathered a record attendance of 7,908 participants this week in Vienna, Austria, a 10-year study, involving over 4,000 UK patients, confirms that a one-week… read more.
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can lead to significant weight loss and improve blood sugar control in adults with severe mental illness, as well as having positive… read more.
Astellas Pharma Incwill present 16 abstracts featuring new data across its approved cancer therapies at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (May 30 –… read more.
Edwards Lifesciences announced that the(FDA has approved its transcatheter aortic valve replacement (TAVR) therapy, the SAPIEN 3 platform, for severe aortic stenosis (AS) patients without symptoms, marking the… read more.
Exposure to junk food advertisements (relative to non-food) results in children and adolescents consuming significantly more calories during the day, regardless of the type of media advertising, according… read more.
Eisai Co., Ltd. announced the presentation of clinical research across its oncology portfolio and pipeline during the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO25), which… read more.
AbbVie announced the FDA has approved Rinvoq (upadacitinib), 15 mg, once daily, for the treatment of adults with giant cell arteritis (GCA). This comes after the European Commission… read more.
A major study of around 260,000 women shows that taking the progesterone-only contraceptive pill can increase asthma attacks in some women. The research, published in ERJ Open Research [1], shows… read more.
AstraZeneca advances its ambition to eliminate cancer as a cause of death with new data across its diverse, industry-leading portfolio and pipeline at the American Society of Clinical… read more.
New subgroup data from the Phase III ARANOTE trial show darolutamide plus androgen deprivation therapy (ADT) improved radiological progression-free survival (rPFS) in patients with high and low-volume metastatic… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
